Recruiting Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant NCT04815356 Conditions Hairy Cell Leukemia, Hairy Cell Leukemia Variant, Hematologic Diseases, +9 more Locations National Institutes of Health Clinical Center — Bethesda, Maryland, United States View Trial Details
Enrolling by Invitation Rituximab+ Zanubrutinib for Patients With Hairy Cell Leukemia and Hairy Cell Variant NCT07690761 Conditions Hairy Cell Leukemia, Hairy Cell Leukemia Variant, Hematologic Diseases, +9 more Locations Bnai Zion — Haifa, Israel View Trial Details
Active, Not Recruiting Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia NCT01841723 Conditions Hairy Cell Leukemia, Hairy Cell Leukemia Variant, Hematologic Diseases, +11 more Locations National Institutes of Health Clinical Center — Bethesda, Maryland, United States Wayne State University/Karmanos Cancer Institute — Detroit, Michigan, United States Mayo Clinic in Rochester — Rochester, Minnesota, United States Ohio State University Comprehensive Cancer Center — Columbus, Ohio, United States View more locations Show fewer locations Loading locations... View Trial Details
